Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.

Abstract

BACKGROUND Intravenous rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B-cell lymphomas (PCBL) has been described in a small number of patients. OBJECTIVES To evaluate the effectiveness, tolerance and adverse effects of ILR in… (More)
DOI: 10.1111/j.1365-2133.2012.10902.x

Topics

  • Presentations referencing similar topics